Literature DB >> 15667145

Toward an optimal procedure for PC-ANN model building: prediction of the carcinogenic activity of a large set of drugs.

Bahram Hemmateenejad1, Mohammad A Safarpour, Ramin Miri, Nasim Nesari.   

Abstract

The performances of the three novel QSAR algorithms, principal component-artificial neural network modeling method combining with three factor selection procedures named eigenvalue ranking, correlation ranking, and genetic algorithm (ER-PC-ANN, CR-PC-ANN, PC-GA-ANN, respectively), are compared by application of these model to the prediction of the carcinogenic activity of a large set of drugs (735 drugs) belonging to a diverse type of compounds. A total number of 1350 theoretical descriptors are calculated for each molecule. The matrix of calculated descriptors (with 735 x 1350 dimension) is subjected to PCA. 95% of the variances in the matrix are explained by the first 137 principal components (PC's). From the pool of 137 PC's, the factor selection methods (ER, CR, and GA) are employed to select the best set of PC's for PC-ANN modeling. In the ER-PC-ANN, the PC's are successively entered into the ANN based on their decreasing eigenvalue. In the CR-PC-ANN, the ANN is first employed to model the nonlinear relationship between each one of the PC's and the carcinogen activity separately. Then, the PC's are ranked based on their decreasing correlating ability and entered to the input layer of the network one after another. Finally, a search algorithm (i.e. genetic algorithm) is used to find the best set of PC's. Both the external and cross-validation methods are used to validate the performances of the resulting models. One is able to see that the results obtained by the PC-GA-ANN and CR-PC-ANN procedures are superior to those resulted from the EV-PC-ANN. Comparison of the results reveals that the results produced by the PC-GA-ANN algorithm are better than those produced by CR-PC-ANN. However, the difference is not significant.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15667145     DOI: 10.1021/ci049766z

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  7 in total

1.  Genetic neural network modeling of the selective inhibition of the intermediate-conductance Ca2+ -activated K+ channel by some triarylmethanes using topological charge indexes descriptors.

Authors:  Julio Caballero; Miguel Garriga; Michael Fernández
Journal:  J Comput Aided Mol Des       Date:  2005-12-23       Impact factor: 3.686

2.  An efficient algorithm coupled with synthetic minority over-sampling technique to classify imbalanced PubChem BioAssay data.

Authors:  Ming Hao; Yanli Wang; Stephen H Bryant
Journal:  Anal Chim Acta       Date:  2013-11-06       Impact factor: 6.558

3.  Linear and nonlinear modeling of antifungal activity of some heterocyclic ring derivatives using multiple linear regression and Bayesian-regularized neural networks.

Authors:  Julio Caballero; Michael Fernández
Journal:  J Mol Model       Date:  2005-10-21       Impact factor: 1.810

4.  Prediction of carcinogenicity for diverse chemicals based on substructure grouping and SVM modeling.

Authors:  Kazutoshi Tanabe; Bono Lučić; Dragan Amić; Takio Kurita; Mikio Kaihara; Natsuo Onodera; Takahiro Suzuki
Journal:  Mol Divers       Date:  2010-02-26       Impact factor: 2.943

5.  Protein hypersaline adaptation: insight from amino acids with machine learning algorithms.

Authors:  Guangya Zhang; Huihua Ge
Journal:  Protein J       Date:  2013-04       Impact factor: 2.371

6.  QSPR Modeling of Bioconcentration Factors of Nonionic Organic Compounds.

Authors:  Omar Deeb; Padmakar V Khadikar; Mohammad Goodarzi
Journal:  Environ Health Insights       Date:  2010-07-06

Review 7.  Considerations and recent advances in QSAR models for cytochrome P450-mediated drug metabolism prediction.

Authors:  Haiyan Li; Jin Sun; Xiaowen Fan; Xiaofan Sui; Lan Zhang; Yongjun Wang; Zhonggui He
Journal:  J Comput Aided Mol Des       Date:  2008-06-24       Impact factor: 3.686

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.